Introduction
HIV-positive MSM are increasingly at risk for developing anal squamous cell carcinoma compared to the general population 1 . Clinics have been set up to detect precursor lesions of anal squamous cell carcinoma, called squamous intraepithelial lesions (SIL) [2] [3] [4] [5] . High-resolution anoscopy (HRA)-guided biopsies are the gold standard for identifying anal SIL. SIL is histopathologically graded anal intraepithelial neoplasia (AIN) 1, 2 or 3 and categorized as low-grade SIL (LSIL; AIN1) or high-grade SIL (HSIL; AIN 2 and 3). The prevalence of histological HSIL (hHSIL) in HIV-positive MSM is around 40% 6 , and as HRA is a costly and cumbersome procedure, more stringent screening criteria for HIV-positive MSM receiving HRA are needed.
Anal cytology can be used for the detection of HSIL (cytological HSIL), but its use is limited by low sensitivity [7] [8] [9] [10] [11] . Several studies have identified risk factors for hHSIL in HIV-positive MSM, but results are not always consistent and studied populations were often relatively small [12] [13] [14] [15] , limiting their potential to identify the patients at highest risk for hHSIL.
We investigated potential demographic and HIV-related risk factors for the presence of histopathologically proven intra-and perianal HSIL in 1681 HIV-positive MSM screened by HRA in Amsterdam, the Netherlands.
Methods
Patients and setting HIV-positive MSM visiting one of three outpatient HIV clinics in Amsterdam, the Netherlands, were offered AIN screening by their HIV-treating physician. The only exclusion criterion was a life expectancy of less than 12 months. HRA was performed by individually trained anoscopists, did not include anal cytology, sexually transmitted disease (STD) or human papillomavirus (HPV) testing and consisted of a digital rectal exam followed by intra-and perianal inspection with a colposcope (ZEISS opmi pico surgical microscope; Oberkochen, Baden-Württemberg, Germany) after repeatedly applying acetic acid (3%-5% solution) and staining with Lugol's iodine when indicated. Lesions suspicious for SIL were biopsied and graded by pathologists specialized in SIL. In clinics A and C pathologists used p16 staining for AIN2 graded biopsies, as described by the College of American Pathologists in The Lower Anogenital Squamous Terminology standardization project, whereas in clinic B, p16 staining was not always used in accordance to the College of American Pathologists Lower Anogenital Squamous Terminology criteria 16 . The highest grade biopsy defined the overall diagnosis.
Data were extracted from the clinical records by two of the investigators (MLSH and EM); behavioral data was patient self-reported to the clinician. HIV-related data were obtained from the Stichting HIV Monitoring database 17 . Data collection was performed using the OpenClinica open source software, version 3.6 (OpenClinica LLC and collaborators, Waltham, Massachisetts, USA).
This study (ref. W15_047 # 15.0058) was approved by the Medical Ethics Review Committee of the Academic Medical Center, Amsterdam, the Netherlands.
Statistical analysis
Only data of the first HRA of each participant were included. Baseline characteristics of the study population were explored using descriptive statistics, comparing characteristics between participants with no dysplasia, LSIL and HSIL using X 2 test for categorical data and one-way analysis of variance, and Kruskal-Wallis test for continuous data.
Assessed outcome variables were: HSIL vs. no SIL, HSIL-AIN2 vs. no SIL, HSIL-AIN3 vs. no SIL, and HSIL vs. no HSIL. Five demographic and seven HIV-related variables were included in univariable logistic regression analysis (Suppl. Table 1 ). For CD4 + cell count and HIV viral load measurements, the measurements closest to the date of HRA were selected. Years living with viral suppression was defined as having a viral load of less than 200 copies/ml in tests from August 1999 onwards, and allowing for one blip in viral load below 400 copies/ml between measurements with viral load less than 200 copies/ml 18 . For samples tested prior to August 1999 the cut-off of detectability of the laboratory assay was the cut-off used to define viral suppression. Multivariable logistic regression analysis was used to determine independent risk factors for HSIL among HIV-positive MSM. All variables that were significantly associated in univariable logistic regression analysis with HSIL diagnosis (at P <0.2, Wald test) were included in the multivariable analysis, as well as the following a priori selected parameters (risk factors for HSIL in other studies 10, [19] [20] [21] [22] ): age at time of HRA, a history of at least one AIDS defining illness, nadir CD4 + cell count, current CD4 + cell count, and years living with viral suppression. A backward selection method was used to create a parsimonious model in which a priori selected variables were forced. We conducted multilevel multivariable logistic regression analyses to correct for potential similarities of participants within each clinic. Multicollinearity was tested with the variance inflation factor and if present, the most objective measurable variable remained in the model, whereas the other variable was dropped. However, the effect of this exclusion was checked in a sensitivity analysis.
To assess whether the effect of risk factors differed by clinic, interaction was tested in themultivariable model. Also, risk factors for HSIL were assessed separately for intraanal and perianal HSIL. Variables were considered significantly associated when P value was less than 0.05. Statistical analyses was performed using Stata (version 13.1; Stata Corp, College Station, Texas, USA).
Results
Characteristics of study population Between 12 February 2008 and 24 November 2015, 1681 HIV-positive MSM underwent their first HRA. Potential risk factors for histological (H)SIL of 311 HIVpositive MSM have been previously described 15 . Three participants were excluded based on the diagnosis of SCC (two intra-anal-and one perianal SCC). The mean age was 49 years (SD 9.6) and 96% of participants used combination antiretroviral therapy (cART). Median duration of cART use was 7.8 years [interquartile range (IQR) 4.0-12.4], median nadir CD4 + cell count was 220 cells/µl (IQR 130-320) and median current CD4 + cell count was 620 cells/µl (IQR 480-790). Only 354 (22%) participants had at least one AIDS-defining illness prior to HRA (Table 1 ). There were some statistically significant (but clinically not important) differences between patients from the three clinics (Suppl. Table  2 ). Of the 1678 HIV-positive MSM, 396 (24%) were diagnosed with AIN1, 289 (17%) with AIN2 and 208 with AIN3 (12%). The prevalence of HSIL was 30% (497/1678 participants). The prevalence of HSIL did not differ significantly between clinics (Suppl. Table 2 ). Compared to participants with no dysplasia, participants with LSIL and HSIL were younger (P<0.001), had more sex partners in the preceding 6 months (P=0.016), had a lower number of years on cART (P<0.001), had a different distribution of nadir CD4 + cell counts (P=0.005), had more often a detectable HIV viral load (P=0.001), and had less years living with viral suppression (P<0.001) ( Table 1) .
Univariable logistic regression analyses
Associated variables for HSIL vs. no SIL in univariable logistic regression analyses were age, duration of cART use, having had an STD in the preceding 6 months, HIV plasma viral load and number of years living with viral suppression. Nadir and current CD4 + cell count were not associated with HSIL. Univariable associations between risk factors and outcome were largely similar between the four outcome measures (Suppl. Table 1 ).
Multivariable logistic regression analyses
In multivariable logistic regression analysis, nested within clinic and comparing HSIL vs. no SIL, increasing age [adjusted odds ratio (aOR) 0.82, 95% confidence interval (CI) 0.70-0.94; P=0.006] and years living with suppressed viral load were significantly protective for HSIL [1 to 5 years viral suppression aOR 0.52 (95% CI 0.34-0.80), 5.01 to 10 years viral suppression aOR 0.47 (95% CI 0.29-0.74), >10 years viral suppression aOR 0.54 (0.34-0.87), all compared to less than 1 year viral suppression, P=0.009]. Outcome measures HSIL-AIN2 vs. no SIL, HSIL-AIN3 vs. no SIL and HSIL vs. no HSIL yielded similar results ( Table 2) .
Based on multicollinearity we excluded a priori cART use, HIV viral load and duration of cART use, because this is largely represented in number of years living with viral suppression. We reran the model including duration of cART use instead of years living with viral suppression, yielding similar results. None of the interaction terms were significant, suggesting that the effect of the included risk factors did not vary by clinic (data not shown).
Additionally, we assessed risk factors for intra-and perianal HSIL vs. no SIL separately. Intra-anal HSIL showed results comparable to the overall model. Only being a current smoker was found to be a significant risk factor of perianal HSIL in multilevel multivariable logistic regression analyses [previously smoked aOR 2.41 (95%CI 0.77-7.57), current smoker aOR 4.90 (95%CI 1.80-13.35), compared to participants who never smoked, P=0.006] ( Supplementary table 3 ).
Discussion
We analyzed potential risk factors for anal HSIL (AIN2-3) in 1678 HIV-positive MSM. Of five demographic and seven HIV-related potential risk factors, only increasing age and years living with suppressed viral load were significantly protective for HSIL vs. no SIL. Sensitivity analyses, including duration of cART use instead of duration of viral suppression, showed a similar relation.
In contrast to our results, several smaller studies, with less than 400 patients each, reported various demographic and HIV-related risk factors that significantly increased the risk for anal hHSIL: the number of specific HPV types and current use of cART 13 , increasing age and CD4 + cell counts less than 50/µl before starting cART 12 , and smoking 23, 24 . We found smoking to be a risk factor, but for perianal HSIL only. We also confirmed that duration of cART use showed a reduced risk for hHSIL 12, 25 . Living more than one year with viral suppression might reduce the risk for hHSIL as it could be a proxy for immune restoration over time. We have no good explanation how older age could be protective for anal HSIL.
The strength of this study is that it reports nearly 1700 patients from three HIV clinics, using hHSIL as an endpoint. This allowed for an extensive multivariable analysis without constraints in the number of covariates.
A limitation of our study is that no data were collected on anal HPV infections, but given that 95% of all HIV-positive MSM have anal HPV present, the value of this risk factor is debatable 13, 26 . More specific, HPV16 testing might be considered to have more discriminatory power, but given that HPV16 was the causative HPV-type in only 60% of anal carcinomas in HIV-positive MSM in another study by our group 27 , 40% of potential anal carcinomas would be missed. Also, patient populations differed significantly between clinics, which may be explained by differences in calendar year of starting with HRA screening and by the large study populations, easily leading to statistically significant but not clinically important differences. Furthermore, multiple anoscopists performed the HRAs, and given the long learning curve for HRA, some HSIL lesions may have been missed 28, 29 . Also, in Clinic B p16 staining was not always used to confirm AIN2 graded biopsies. Finally, social desirability bias might have occurred for self-reported STDs and sexual behavior.
Young HIV-positive MSM without viral suppression are statistically at highest risk for HSIL, but given the high prevalence of HSIL among all virally suppressed men, we advise that all HIV-positive MSM should be screened for the presence of anal HSIL. 
Supplementary table 1 -Univariable riskfactors for anal histology-proven HSIL, defined as (1) HSIL vs no SIL; (2) AIN2 vs no SIL; (3) AIN3 vs noSIL; (4)

HSIL vs no HSIL (including AIN1) among HIV-positive MSM in Amsterdam, the Netherlands (AIN Cohort Study, 2016).
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